Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Trends in darunavir resistance-associated mutations and phenotypic resistance in commercially tested United States clinical samples between 2006 and 2012.

AIDS research and human retroviruses - 1 Jun 2015

Lathouwers Erkki, Gupta Soumi, Haddad Mojgan, Paquet Agnes, de Meyer Sandra, Baugh Bryan

Abstract excerpt

HIV-1 samples submitted by clinicians from the United States for routine drug susceptibility testing (PhenoSense GT) were evaluated for genotypic and phenotypic resistance to darunavir and other protease inhibitors (PIs). Among these samples (Monogram Biosciences database January 2006-June 2012; N=78,843), isolates harboring zero IAS-USA darunavir resistance-associated mutations (RAMs) increased from 77.7% in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to Darunavir

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Viral

Share to HIV Infections

Share to Microbial Sensitivity Tests

Share to Prevalence

Share to United States

Source

Identifiers

PMID: 25684627
DOI: 10.1089/AID.2014.0020

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Trends in darunavir resistance-associated mutations and phenotypic resistance in commercially tested United States clinical samples between 2006 and 2012.PMID 25684627Read ↗

Prevalence of Darunavir Resistance in the United States from 2010 to 2017.Semantic proximity Read ↗

Changes from 2000 to 2009 in the Prevalence of HIV-1 Containing Drug Resistance-Associated Mutations from Antiretroviral Therapy-Naive, HIV-1-Infected Patients in the United States.Semantic proximity Read ↗

HIV-1 resistance rarely observed in patients using darunavir once-daily regimens across clinical studies.Semantic proximity Read ↗

Short communication: Phenotypic protease inhibitor resistance and cross-resistance in the clinic from 2006 to 2008 and mutational prevalences in HIV from patients with discordant tipranavir and darunavir susceptibility phenotypes.Semantic proximity Read ↗

Temporal Trends in HIV-1 Mutations Used for the Surveillance of Transmitted Drug Resistance.Semantic proximity Read ↗

Genotypic resistance profiles associated with virological failure to darunavir-containing regimens: a cross-sectional analysis.Semantic proximity Read ↗

Recent trends and patterns in HIV ‐1 transmitted drug resistance in the United KingdomSemantic proximity Read ↗

Short communication prevalence of susceptibility to etravirine by genotype and phenotype in samples received for routine HIV type 1 resistance testing in the United States.Semantic proximity Read ↗

Clinical outcomes of once-daily darunavir in treatment-experienced patients with darunavir resistance-associated mutations through 48 weeks of treatment.Semantic proximity Read ↗

Prevalence of antiretroviral drug resistance and resistance-associated mutations in antiretroviral therapy-naïve HIV-infected individuals from 40 United States cities.Semantic proximity Read ↗

Prevalence in the USA of rilpivirine resistance-associated mutations in clinical samples and effects on phenotypic susceptibility to rilpivirine and etravirine.Semantic proximity Read ↗

HIV-1 DNA Testing in Viremic Patients Identifies More Drug Resistance Than HIV-1 RNA TestingSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.